Log In
Print
BCIQ
Print
Print this Print this
 

ALTU-237

  Manage Alerts
Collapse Summary General Information
Company Ajinomoto Co. Inc.
DescriptionCrystalline formulation of an oxalate-degrading enzyme
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase I
Standard IndicationHyperoxaluria
Indication DetailsTreat hyperoxaluria
Regulatory Designation

Partner

Allena Pharmaceuticals Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today